Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDX3X | O00571 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 12/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.49 |
| ▸ | LMNA | P02545 | 5/20 | 0.49 |
| ▸ | MEN1 | O00255 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | CCR6 | P51684 | 1/20 | 0.49 |
| ▸ | BLM | P54132 | 1/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22737561 | 0.89 | GBA1 (0.49) | DDX3XTDP1MAPTKMT2ALMNA | |
| SCHEMBL14527861 | 0.84 | DDX3X (0.60) | DDX3XTDP1MAPTKMT2ALMNA | |
| SCHEMBL22737390 | 0.84 | GBA1 (0.47) | TDP1MAPTKMT2ALMNAMEN1 | |
| SCHEMBL11913671 | 0.83 | DDX3X (0.82) | DDX3XTDP1MAPTKMT2ALMNA | |
| SCHEMBL12685994 | 0.75 | MAPT (0.71) | MAPTKMT2ALMNAMEN1KDM4E | |
| SCHEMBL8238479 | 0.73 | MAPT (0.61) | DDX3XMAPTKMT2ALMNAMEN1 | |
| SCHEMBL15890518 | 0.73 | MTOR (0.65) | TDP1MAPTKMT2ALMNAMEN1 | |
| SCHEMBL3327945 | 0.73 | MTOR (0.60) | MAPTKMT2ALMNAMEN1KDM4E | |
| SCHEMBL3327950 | 0.73 | MTOR (0.60) | MAPTKMT2ALMNAMEN1KDM4E | |
| SCHEMBL8241042 | 0.72 | TDP1 (0.84) | TDP1MAPTKMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200375996-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS BY RESCUING ALPHA-SYNUCLEIN TOXICITY | D.E. SHAW RESEARCH, LLC (US) | 2020-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200375996-A1 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS BY RESCUING ALPHA-SYNUCLEIN TOXICITY | SNCA, PARK7, NEDD4 | DDX3X 1346/4885TDP1 367/4885MAPT 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.